Across TCGA pan-cancer cohorts, KIF18B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KIF18B data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher KIF18B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KIF18B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ACC, KICH, and COAD are the cancer types where KIF18B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
COAD	DFS	Median	III,IV	0.035	0.698	<.001	12	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
SKCM	OS	Median	All	1.000	0.867	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: KIF18B tumor-vs-normal RNA expression · all KIF18B data types